Inclusion Criteria:

1. Be capable of understanding the informed consent form (ICF) and complying with the
protocol, and must sign the ICF prior to the performance of any study related
procedures;

2. Have cancer that is nonresponsive despite prior treatment with current standard of
care regimens or for whom there are no available effective therapies;

3. Have measurable or evaluable neoplastic disease;

4. Be greater than or equal to age 18;

5. Have and ECOG Performance Status score of less than or equal to 2;

6. Have adequate organ function defined by:

1. Liver function tests (AST & ALT) less than or equal to 3 times the upper limit
of normal (ULN);

2. Bilirubin less than or equal to 1.5 X ULN;

3. Serum Creatinine less than or equal to 1.5 X ULN;

4. Hemoglobin greater than or equal to 8.0 g/dL;

7. Have recovered or stabilized from clinically significant toxicities of prior
chemotherapy, surgery, or radiotherapy;

8. Have left ventricular ejection fraction (LVEF) of greater than or equal to 45% by
multiple gated acquisition (MUGA) scan or echocardiogram.

Exclusion Criteria:

1. Have had a prior serious, uncontrollable hypersensitivity reaction to Cremophor EL;

2. Be pregnant or lactating (women of childbearing potential must use appropriate birth
control (abstinence, barrier methods, oral contraceptives and/or intrauterine
devices) during the entire duration of the study, or the patient must be surgically
sterile (with documentation in the patient's medical records);

3. Receive any other anticancer treatment or investigational therapy within 14 days
prior to day 1; or within 6 weeks after prior mitomycin C or nitrosourea. Patients
with advanced prostate cancer may continue to receive leutinizing hormone-releasing
hormone (LHRH) therapy while in this study;

4. Have previously enrolled in this trial. -